Contact
Diario Médico reports on the new European consortium lead by IRB Barcelona that is searching for new compounds to prevent diabetes and obesity. DIOMED ('Diabetes, obesity and medicine'), which kicks off on 22 May, will run for 3 years and is funded with 813,673 € through the EU's Territorial Cooperation Programme for South-west Europe (Interreg IV-SUDOE), which supports transnational and inter-regional innovation projects.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
